Home   >  
Cell Cycle/DNA Damage

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
NXT629 Chemical Structure
BCP44937 NXT629 1454925-59-7
NXT629 is a potent, selective, and competitive PPAR-α antagonist.
EHP-101 Chemical Structure
BCP43165 EHP-101 1818428-24-8
EHP-101 is an oral lipidic formulation of VCE-004.8 that has shown efficacy in several preclinical models of autoimmune, inflammatory, fibrotic, and neurodegenerative diseases.
Fmoc-L-Leucine Chemical Structure
BCP39156 Fmoc-L-Leucine 35661-60-0
NPC 15199 is an amino acid derivative.
Lobeglitazone Chemical Structure
BCP37672 Lobeglitazone 607723-33-1
Lobeglitazone is an agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic activity. Besides its activation of peroxisome proliferator-activated receptor (PPAR) gamma, lobeglitazone is also a potent agonist for PPARalpha.
GW6471 Chemical Structure
BCP35208 GW6471 880635-03-0
GW 6471 is a potent PPARα antagonist.
LY518674 Chemical Structure
BCP34904 LY518674 425671-29-0
LY518674 is a potent, selective PPARα antagonist, with an EC50 of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis.
GW6471 Chemical Structure
BCP33242 GW6471 436159-64-7
GW6471 is a potent PPARα antagonist.
Sipoglitazar Chemical Structure
BCP33099 Sipoglitazar 342026-92-0
Sipoglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist, with hypoglycemic activity.
Tesaglitazar Chemical Structure
BCP23582 Tesaglitazar 251565-85-2
Tesaglitazar is a PPAR agonist potentially for the treatment of type 2 diabetes. The drug had completed several phase III clinical trials, however in May, 2006 AstraZeneca announced that it had discontinued further development.
Pioditazone hydrochloride Chemical Structure
BCP22942 Pioditazone hydrochloride 112529-15-4
Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
123下一页末页共 51 条记录 1 / 6 页